These results compared favorably with a prior phase 2 trial assessing the efficacy of pembrolizumab alone in individuals with cervical cancer that were previously treated, in which all responses were seen in patients with PD-L1-positive tumors (CPS ≥ 1)41. The gene discussed is CD274; the disease is cervical carcinoma.